[
    {
        "file_name": "coherusbiosciencesinc_20200227_10-k_ex-10.29_12021376_ex-10.29_development agreement.pdf",
        "perturbation": [
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "1.39\nLicensed Product means the finished dosage forms (including final packaging) of the biosimilars containing Ranibizumab which have been Developed and/or are being Developed by Bioeq to each of the Existing Reference Products ([***]).\nFor clarity, Licensed Products include without limitation Vial Products and PFS Products, and shall extend to any New Products to the extent this Agreement is amended in accordance with Section 3.4",
                "changed_text": "1.39\nLicensed Product means only the finished dosage forms (excluding final packaging) of the biosimilars containing Ranibizumab which have been Developed and/or are being Developed by Bioeq to each of the Existing Reference Products ([***]).\nFor clarity, Licensed Products include only Vial Products and PFS Products, and shall not extend to any New Products under any circumstances.",
                "explanation": "The original definition includes final packaging and extends to new products under certain conditions. The modified definition explicitly excludes final packaging and new products. This creates a contradiction because other sections of the contract may refer to 'Licensed Products' with the assumption of including final packaging or the possibility of including new products. This will create **uncertainty in contractual obligations**.",
                "location": "Section 1.39"
            },
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "1.15\nControl (whether used as a noun or as a verb) or Controlled means, with respect to any Intellectual Property\nRight, Trademark or Know-How, the possession (whether by ownership or license, other than pursuant to this Agreement) by a Party\nof the ability to grant to the other Party access or a license as provided herein under such Intellectual Property Right, Trademark or\nKnow-How without violating the terms of any agreement or other arrangements with any Third Party.",
                "changed_text": "1.15\nControl (whether used as a noun or as a verb) or Controlled means, with respect to any Intellectual Property\nRight, Trademark or Know-How, the possession (whether by ownership or license, other than pursuant to this Agreement) by a Party\nof the ability to grant to the other Party access or a license as provided herein under such Intellectual Property Right, Trademark or\nKnow-How. Violating the terms of any agreement or other arrangements with any Third Party is allowed.",
                "explanation": "The first definition says the ability to grant access should not violate agreements with third parties. The modified definition says violating agreement is allowed. This creates a contradiction that will create disputes over the ability to grant licenses to intellectual property.",
                "location": "Section 1.15"
            },
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "15.3.1\nSale of Inventory. Licensee shall be permitted, at Bioeq’s choice (if this Agreement is terminated by Bioeq\npursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5) or at Licensee’s choice\n(if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8), to cither (a) continue selling its and\nits Affiliates’ inventory of Licensed Products existing on the termination effective date in accordance with this Agreement for a\nmaximum period of [***] ([***]) days (in which case all terms and conditions of this Agreement, including Licensee’s obligation to\nreport and pay royalties, shall continue to apply to such continued sale) or (b) sell such inventory to Bioeq at the supply price paid by\nLicensee to Bioeq for such inventory in accordance with the Manufacturing and Supply Agreement.",
                "changed_text": "15.3.1\nSale of Inventory. Licensee is required, at Bioeq’s choice (if this Agreement is terminated by Bioeq\npursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5) or at Licensee’s choice\n(if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8), to either (a) immediately cease the selling its and\nits Affiliates’ inventory of Licensed Products existing on the termination effective date and destroy them or (b) sell such inventory to Bioeq at twice the original price paid by\nLicensee to Bioeq for such inventory in accordance with the Manufacturing and Supply Agreement.",
                "explanation": "The original definition allows continued sales for a certain period but the modified definition prevents sales and orders destruction or selling the inventory to Bioeq at twice the original price paid. This contradiction will create uncertainty because other sections of the contract may refer to 'Sale of Inventory' with the assumption of continued sale or the possibility of Licensee not selling.",
                "location": "Section 15.3.1"
            }
        ]
    }
]